Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey
Language English Country Germany Media print-electronic
Document type Letter
PubMed
38388854
PubMed Central
PMC11143019
DOI
10.1007/s15010-023-02169-7
PII: 10.1007/s15010-023-02169-7
Knihovny.cz E-resources
- MeSH
- COVID-19 * epidemiology MeSH
- Adult MeSH
- Hematologic Neoplasms * complications epidemiology MeSH
- Intensive Care Units * statistics & numerical data MeSH
- Critical Illness * MeSH
- Middle Aged MeSH
- Humans MeSH
- Surveys and Questionnaires MeSH
- SARS-CoV-2 * MeSH
- Aged MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Letter MeSH
Aga Khan University Karachi Pakistan
Amsterdam UMC location VUmc Amsterdam Netherlands
Ankara University Ankara Turkey
ASST Grande Ospedale Metropolitano Niguarda Milan Italy
Azienda Ospedaliera Nazionale SS Antonio e Biagio e Cesare Arrigo Alessandria Italy
Azienda Ospedaliera San Gerardo Monza Monza Italy
Azienda Sanitaria Universitaria del Friuli Centrale Udine Italy
Center for Radiology University Clinical Center of Serbia Belgrade Serbia
Centre Hospitalier de Versailles Versailles France
Centro Hospitalar e Universitário São João Porto Portugal
CIBERINFEC Instituto de Salud Carlos 3 Madrid Spain
Clinic for Orthopedic Surgery and Traumatology University Clinical Center of Serbia Belgrade Serbia
Communicable Disease Center Hamad Medical Corporation Doha Qatar
Complejo Hospitalario de Navarra Iruña Pamplona Spain
COVID hospital Batajnica Belgrade Serbia
Departament de Medicina Universitat Autònoma de Barcelona Bellaterra Spain
Department of Clinical and Biological Sciences University of Turin Turin Italy
Department of Hematology and Oncology Comprehensive Cancer Center Innsbruck Innsbruck Austria
Department of Hematology and Oncology Medical University of Innsbruck Innsbruck Austria
Department of Hematology Copenhagen University Hospital Rigshospitalet Copenhagen Denmark
Department of Hematology Hospital Universitario de Burgos Burgos Spain
Department of Hematology Research Unit Hospital Universitario de Burgos Burgos Spain
Department of Hematology University Hospital Dubrava Zagreb Croatia
Department of Infectious Diseases Karolinska University Hospital Stockholm Sweden
Department of Internal Medicine ADRZ Goes Netherlands
Department of Medicine Section of Hematology University of Verona Verona Italy
Department of Medicine University Medical Center Hamburg Eppendorf Hamburg Germany
Department of Nephrology and Infectious Diseases AZ Sint Jan Brugge Oostende AV Brugge Belgium
Division of Hematology and Oncology Weill Cornell Medicine New York USA
Division of Hematology Dokuz Eylul University Izmir Turkey
Ematologia con Trapianto Ospedale Dimiccoli Barletta Barletta Italy
Facultad de Ciencias de la Salud Universidad Isabel 1 Burgos Spain
Federal University of Rio de Janeiro Rio de Janeiro Brazil
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Italy
Fundacion Jimenez Diaz University Hospital Health Research Institute IIS FJD Madrid Spain
German Centre for Infection Research Partner Site Bonn Cologne Cologne Germany
Hematology and Stem Cell Transplan Unit Vito Fazzi Hospital Lecce Italy
Hematology and Stem Cell Transplant Unit IRCCS Regina Elena National Cancer Institute Rome Italy
Hematology Department Hospital General Universitario Gregorio Marañón Madrid Spain
Hematology Department Hospital Universitario de Salamanca Salamanca Spain
Hematology Department of Biomedicine and Prevention University of Rome Tor Vergata Rome Italy
Hematology Unit ASST Spedali Civili Brescia Italy
Hematology Unit Center for Translational Medicine Azienda USL Toscana NordOvest Leghorn Italy
Hematology Unit Fondazione Policlinico Universitario Agostino Gemelli IRCCS Rome Italy
Hematology Unit Università Cattolica del Sacro Cuore Rome Italy
Hospital Clinic Barcelona Spain
Hospital Escuela de Agudos Dr Ramón Madariaga Posadas Argentina
Hospital Nuestra Señora de Sonsoles Ávila Spain
Hospital Universitario Marqués de Valdecilla Santander Spain
Hospital Universitario Puerta de Hierro Majadahonda Spain
Hospital University of Parma Hematology and Bone Marrow Unit Parma Italy
IBSAL Centro de Investigación del Cáncer IBMCC Salamanca Spain
Institute of Hematology and Blood Transfusion Prague Czech Republic
IRCCS Ospedale San Raffaele Milan Italy
King's College Hospital London UK
King's College London London UK
La Paz University Hospital Madrid Spain
Medical University of Graz Graz Austria
Medizinische Klinik 2 Klinikum rechts der Isar TU München Munich Germany
NIHR Oxford Biomedical Research Centre Churchill Hospital Oxford UK
Oncology Center Mansoura University Mansoura Egypt
Ospedale Policlinico San Martino Genoa Italy
Portuguese Institute of Oncology Lisbon Portugal
San Luigi Gonzaga Hospital Orbassano Orbassano Italy
Stem Cell Transplant Center AOU Citta' della Salute e della Scienza Turin Italy
Università Milano Bicocca Milan Italy
University Clinic of Hematology Skopje North Macedonia
University Clinical Center Serbia Medical Faculty University Belgrade Belgrade Serbia
University Hospital Centre Rijeka Rijeka Croatia
University Hospital Hradec Králové Hradec Králové Czech Republic
University Hospital Olomouc Olomouc Czech Republic
University Medical Center Groningen Groningen Netherlands
University of Milan and Fondazione IRCCS Istituto Nazionale Dei Tumori Milan Italy
See more in PubMed
Dennler U, Geisler F, Spinner CD. Declining COVID-19 morbidity and case fatality in Germany: the pandemic end? Infection. 2022;50:1625–1626. doi: 10.1007/s15010-022-01873-0. PubMed DOI PMC
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–1062. doi: 10.1016/S0140-6736(20)30566-3. PubMed DOI PMC
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the chinese center for disease control and prevention. JAMA. 2020;323:1239–1242. doi: 10.1001/jama.2020.2648. PubMed DOI
Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136:2881–2892. doi: 10.1182/blood.2020008824. PubMed DOI PMC
Wood WA, Neuberg DS, Thompson JC, et al. Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub. Blood Adv. 2020;4:5966–5975. doi: 10.1182/bloodadvances.2020003170. PubMed DOI PMC
Yigenoglu TN, Ata N, Altuntas F, et al. The outcome of COVID-19 in patients with hematological malignancy. J Med Virol. 2021;93:1099–1104. doi: 10.1002/jmv.26404. PubMed DOI PMC
Pagano L, Salmanton-Garcia J, Marchesi F, et al. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA) J Hematol Oncol. 2021;14:168. doi: 10.1186/s13045-021-01177-0. PubMed DOI PMC
Busca A, Salmanton-Garcia J, Corradini P, et al. COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP. Blood Adv. 2022;6:2427–2433. doi: 10.1182/bloodadvances.2021005616. PubMed DOI PMC
Infante MS, Salmanton-Garcia J, Fernandez-Cruz A, et al. B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: a European Hematology Association Survey (EPICOVIDEHA) Front Oncol. 2022;12:992137. doi: 10.3389/fonc.2022.992137. PubMed DOI PMC
Lamure S, Salmanton-Garcia J, Robin-Marieton E, et al. COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey. Blood Adv. 2022;6:3870–3874. doi: 10.1182/bloodadvances.2022007357. PubMed DOI PMC
Busca A, Salmanton-Garcia J, Marchesi F, et al. Outcome of COVID-19 in allogeneic stem cell transplant recipients: results from the EPICOVIDEHA registry. Front Immunol. 2023;14:1125030. doi: 10.3389/fimmu.2023.1125030. PubMed DOI PMC
Criscuolo M, Salmanton-Garcia J, Fracchiolla N, et al. SARS-CoV-2 infection in patients with mastocytosis: an EPICOVIDEHA report. J Investig Allergol Clin Immunol. 2023;33:225–227. doi: 10.18176/jiaci.0845. PubMed DOI
Marchesi F, Salmanton-Garcia J, Emarah Z, et al. COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA) Haematologica. 2023;108:22–33. doi: 10.3324/haematol.2022.280847. PubMed DOI PMC
Marchetti M, Salmanton-Garcia J, El-Ashwah S, et al. Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry. Ther Adv Hematol. 2023;14:20406207231154706. doi: 10.1177/20406207231154706. PubMed DOI PMC
van Doesum JA, Salmanton-Garcia J, Marchesi F, et al. Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey. Blood Adv. 2023;7:2645–2655. doi: 10.1182/bloodadvances.2022009578. PubMed DOI PMC
Hajjar LA, Costa I, Rizk SI, et al. Intensive care management of patients with COVID-19: a practical approach. Ann Intensive Care. 2021;11:36. doi: 10.1186/s13613-021-00820-w. PubMed DOI PMC
Ramos R, de la Villa S, Garcia-Ramos S, et al. COVID-19 associated infections in the ICU setting: a retrospective analysis in a tertiary-care hospital. Enferm Infecc Microbiol Clin. 2023;41:278–283. doi: 10.1016/j.eimc.2021.10.014. PubMed DOI PMC
Rama-Maceiras P, Sanduende Y, Taboada M, et al. Critical patients COVID-19 has changed the management and outcomes in the ICU after 1 year of the pandemic? A multicenter, prospective, observational study. Enferm Infecc Microbiol Clin (Engl Ed) 2023;41:70–78. doi: 10.1016/j.eimc.2021.06.016. PubMed DOI PMC
Denkinger CM, Janssen M, Schakel U, et al. Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial. Nat Cancer. 2023;4:96–107. PubMed PMC
Network C-IGobotR, the C-ICUI. Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study. Intens Care Med. 2021;47:60–73. PubMed PMC
Salmanton-Garcia J, Busca A, Cornely OA, et al. EPICOVIDEHA: a ready to use platform for epidemiological studies in hematological patients with COVID-19. Hemasphere. 2021;5:e612. doi: 10.1097/HS9.0000000000000612. PubMed DOI PMC
Robilotti EV, Babady NE, Mead PA, et al. Determinants of COVID-19 disease severity in patients with cancer. Nat Med. 2020;26:1218–1223. doi: 10.1038/s41591-020-0979-0. PubMed DOI PMC
Pagano L, Salmanton-Garcia J, Marchesi F, et al. COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA. Blood. 2022;139:1588–1592. doi: 10.1182/blood.2021014124. PubMed DOI PMC
Pagano L, Salmanton-Garcia J, Marchesi F, et al. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey. Blood. 2022;140:2773–2787. doi: 10.1182/blood.2022017257. PubMed DOI PMC
Salmanton-Garcia J, Marchesi F, Glenthoj A, et al. Improved clinical outcome of COVID-19 in hematologic malignancy patients receiving a fourth dose of anti-SARS-CoV-2 vaccine: an EPICOVIDEHA report. Hemasphere. 2022;6(11):e789. doi: 10.1097/HS9.0000000000000789. PubMed DOI PMC
Blennow O, Salmanton-Garcia J, Nowak P, et al. Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report. Am J Hematol. 2022;97:E312–E317. doi: 10.1002/ajh.26626. PubMed DOI PMC
Shields AM, Burns SO, Savic S, Richter AG. Consortium UPC-COVID-19 in patients with primary and secondary immunodeficiency: the United Kingdom experience. J Allergy Clin Immunol. 2021;147(3):870–5 e1. doi: 10.1016/j.jaci.2020.12.620. PubMed DOI PMC
Greco M, De Corte T, Ercole A, et al. Clinical and organizational factors associated with mortality during the peak of first COVID-19 wave: the global UNITE-COVID study. Intens Care Med. 2022;48:690–705. doi: 10.1007/s00134-022-06705-1. PubMed DOI PMC
Paparoupa M, Schroder AS, Braunsteiner J, et al. The effects of SARS-CoV-2 virus type and of vaccination status on causes of death over the course of the COVID-19 pandemic. Dtsch Arztebl Int. 2022;119:607–608. PubMed PMC
Tandon P, Leibner E, Hackett A, et al. The fourth wave: vaccination status and intensive care unit mortality at a large hospital system in New York City. Acute Crit Care. 2022;37:339–346. doi: 10.4266/acc.2022.00675. PubMed DOI PMC
Taylor K, Rivere E, Jagneaux T, et al. Clinical characteristics and outcomes of SARS-Cov-2 B.1.1.529 infections in hospitalized patients and multi-surge comparison in Louisiana. PLoS ONE. 2022;17:e0268853. doi: 10.1371/journal.pone.0268853. PubMed DOI PMC
de Prost N, Audureau E, Heming N, et al. Clinical phenotypes and outcomes associated with SARS-CoV-2 variant Omicron in critically ill French patients with COVID-19. Nat Commun. 2022;13(1):6025. doi: 10.1038/s41467-022-33801-z. PubMed DOI PMC
Gong X, Khan A, Wani MY, Ahmad A, Duse A. COVID-19: a state of art on immunological responses, mutations, and treatment modalities in riposte. J Infect Public Health. 2023;16(2):233–249. doi: 10.1016/j.jiph.2022.12.019. PubMed DOI PMC
Hensley MK, Prescott HC. Caring for the critically Ill patient with COVID-19. Clin Chest Med. 2022;43(3):441–456. doi: 10.1016/j.ccm.2022.04.006. PubMed DOI PMC
Salmanton-Garcia J, Marchesi F, Gomes da Silva M, et al. Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry. EClini Med. 2023;58:101939. PubMed PMC
Marchesi F, Salmanton-Garcia J, Buquicchio C, et al. Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry. J Hematol Oncol. 2023;16:32. doi: 10.1186/s13045-023-01423-7. PubMed DOI PMC
Writing Committee for the R-CAPI. Higgins AM, Berry LR, et al. Long-term (180-day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial. JAMA. 2023;329:39–51. doi: 10.1001/jama.2022.23257. PubMed DOI PMC
Bilich T, Roerden M, Maringer Y, et al. Preexisting and post-COVID-19 immune responses to SARS-CoV-2 in patients with cancer. Cancer Discov. 2021;11:1982–1995. doi: 10.1158/2159-8290.CD-21-0191. PubMed DOI
Cattaneo C, Salmanton-Garcia J, Marchesi F, et al. Simultaneous onset of haematological malignancy and COVID: an epicovideha survey. Cancers (Basel) 2022;14:1. doi: 10.3390/cancers14225530. PubMed DOI PMC
Agrawal U, Bedston S, McCowan C, et al. Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales. Lancet. 2022;400:1305–1320. doi: 10.1016/S0140-6736(22)01656-7. PubMed DOI PMC
Lerner AH, Arvanitis P, Vieira K, Klein EJ, Farmakiotis D. mRNA vaccination decreases COVID-19-associated morbidity and mortality among organ transplant recipients: a contemporary cohort study. Open Forum Infect Dis. 2022;9:ofac503. doi: 10.1093/ofid/ofac503. PubMed DOI PMC
Spring J, Munshi L. Hematology emergencies in adults with critical illness: malignant hematology. Chest. 2022;162:120–131. doi: 10.1016/j.chest.2022.02.004. PubMed DOI
Kochanek M, Kochanek J, Boll B, et al. Veno-venous extracorporeal membrane oxygenation (vv-ECMO) for severe respiratory failure in adult cancer patients: a retrospective multicenter analysis. Intens Care Med. 2022;48:332–342. doi: 10.1007/s00134-022-06635-y. PubMed DOI PMC
